David Pace

Summary

Publications

  1. doi request reprint Quadrivalent meningococcal conjugate vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 27:B30-41. 2009
  2. doi request reprint Meningococcal disease: clinical presentation and sequelae
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 30:B3-9. 2012
  3. doi request reprint Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
    David Pace
    Malta Children s Vaccine Group, Mater Dei Hospital, Tal Qroqq, Msida MSD 2090, Malta Electronic address
    Vaccine . 2016
  4. pmc Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial
    David Pace
    Malta Children s Vaccine Group, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    BMJ 350:h1554. 2015
  5. doi request reprint Leishmaniasis
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida MSD 2090, Malta Electronic address
    J Infect 69:S10-8. 2014
  6. doi request reprint Glycoconjugate vaccines
    David Pace
    Mater Dei Hospital, Department of Paediatrics, Msida, Malta
    Expert Opin Biol Ther 13:11-33. 2013
  7. doi request reprint Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Future Microbiol 5:1629-40. 2010
  8. pmc Manifestations of paediatric Leishmania infantum infections in Malta
    David Pace
    Paediatric Infectious Diseases Clinic, Mater Dei Hospital, Msida, Malta
    Travel Med Infect Dis 9:37-46. 2011
  9. doi request reprint Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Expert Rev Vaccines 8:529-42. 2009
  10. doi request reprint Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, MSD, Malta
    Vaccine 26:5952-6. 2008

Collaborators

Detail Information

Publications13

  1. doi request reprint Quadrivalent meningococcal conjugate vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 27:B30-41. 2009
    ..This vaccine and others in development offer the potential to broaden population protection against meningococcal disease...
  2. doi request reprint Meningococcal disease: clinical presentation and sequelae
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    Vaccine 30:B3-9. 2012
    ..The only rational approach to the prevention of meningococcal disease and the associated human suffering is through vaccination...
  3. doi request reprint Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
    David Pace
    Malta Children s Vaccine Group, Mater Dei Hospital, Tal Qroqq, Msida MSD 2090, Malta Electronic address
    Vaccine . 2016
    ..For this reason, MenCC vaccines are now used as probes of immunologic memory, however, no studies have demonstrated their ability to distinguish primed from unprimed children...
  4. pmc Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial
    David Pace
    Malta Children s Vaccine Group, Mater Dei Hospital, Tal Qroqq, Msida, MSD 2090, Malta
    BMJ 350:h1554. 2015
    ..To determine whether the immunogenicity of a single dose infant priming schedule of serogroup C meningococcal (MenC) conjugate vaccine is non-inferior to a two dose priming schedule when followed by a booster dose at age 12 months...
  5. doi request reprint Leishmaniasis
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida MSD 2090, Malta Electronic address
    J Infect 69:S10-8. 2014
    ..The persistent lack of a vaccine against human leishmaniasis is a result of the poor investment in this neglected parasitosis. ..
  6. doi request reprint Glycoconjugate vaccines
    David Pace
    Mater Dei Hospital, Department of Paediatrics, Msida, Malta
    Expert Opin Biol Ther 13:11-33. 2013
    ..Death or disability may be the potential aftermath of invasive infections with these pathogens. Active immunisation is the only rational approach in preventing such infections...
  7. doi request reprint Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Future Microbiol 5:1629-40. 2010
    ..In Europe, MenACWY-CRM is the first quadrivalent meningococcal glycoconjugate vaccine available to provide broader protection against Neisseria meningitidis serogroups A, C, W-135 and Y...
  8. pmc Manifestations of paediatric Leishmania infantum infections in Malta
    David Pace
    Paediatric Infectious Diseases Clinic, Mater Dei Hospital, Msida, Malta
    Travel Med Infect Dis 9:37-46. 2011
    ..Leishmaniasis should be included in the differential diagnosis of fever and hepatosplenomegaly or chronic cutaneous lesions in children who travel to Malta...
  9. doi request reprint Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy
    David Pace
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Expert Rev Vaccines 8:529-42. 2009
    ..This article discusses this novel quadrivalent vaccine formulation and its potential to control invasive disease caused by N. meningitidis serogroups A, C, Y and W-135...
  10. doi request reprint Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines
    David Pace
    Department of Paediatrics, Mater Dei Hospital, MSD, Malta
    Vaccine 26:5952-6. 2008
    ....
  11. ncbi request reprint MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection
    David Pace
    Mater Dei Hospital, Department of Paediatrics, Tal Qroqq, Msida, MSD 2090, Malta
    Curr Opin Mol Ther 11:692-706. 2009
    ....
  12. doi request reprint Adequacy of pediatric triage
    Pharrah Debono
    Department of Paediatrics, Mater Dei Hospital, Tal Qroqq, Msida, Malta
    Disaster Med Public Health Prep 6:151-4. 2012
    ..To assess the adequacy of the pediatric triage system in an acute care general hospital...
  13. doi request reprint Quest for the diagnosis. Case 1: a neonatal zoonosis. Neonatal Pasteurella multocida septicaemia
    David Pace
    Department of Paediatrics, St Luke s Hospital, Guardamangia, Malta
    Acta Paediatr 97:250-2. 2008